Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986482 alone or in combination in advanced solid tumors
NL-OMON60554Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-986482 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma, colorectal cancer (CRC), breast cancer, sponsored by Bristol Myers Squibb. Started Nov 2025; status: recruiting.
02
Drugs
BMS-986482
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanomacolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NL-OMON60554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60554.